Open Trials

Ovary

AGO-OVAR 27

Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)

WoO: Window of Opportunity trial of Olaparib and Durvalumab in histologically proven EOC

AGO-OVAR 2.29

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial

AGO-OVAR 2.34 / MIROVA

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy

AGO-OVAR 2.36 / MIRASOL

A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

Ovary / Endometrium / Cervix

Surgical issues

AGO-OVAR OP.6 ECLAT

Pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer at high risk of recurrence. A multicenter, prospective randomized controlled trial.

AGO-OVAR OP.9 SENTICOL III

International validation study of sentinel node biopsy in early cervical cancer